Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06637150
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-09-28
Brief Title:
Dalpicilib-Enhanced Vs Standard Endocrine Therapy in ER HER2- Early Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase III Randomized Controlled Trial Comparing Dalpicilib-Enhanced Adjuvant Endocrine Therapy with Standard Adjuvant Endocrine Therapy in ER HER2- Lymph Node-Negative Early Breast Cancer with Risk Factors
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive HER2-negative lymph node-negative patients with risk factors in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None